Related Experiment Video

Updated: Jul 13, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib-responsive actinic keratoses

Jean-Francois Hermanns1, Gerald E Piérard, Pascale Quatresooz

  • 1Department of Dermatopathology, University Hospital of Liège, B-4000 Liège, Belgium.

Oncology Reports
|August 3, 2007
PubMed

Insights

Erlotinib, an EGFR inhibitor for cancer, incidentally caused inflammation and regression in actinic keratoses, a skin condition. This skin reaction may predict the drug

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Erlotinib is a targeted therapy inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase.
  • It is primarily used for advanced non-small-cell lung carcinoma and other solid tumors.
  • EGFR inhibitors commonly cause skin toxicities, such as acneiform eruptions.

Observation:

  • The study observed an incidental effect of erlotinib on actinic keratoses (AKs).
  • Actinic keratoses are pre-malignant skin lesions.
  • These lesions exhibited marked inflammation and partial regression during erlotinib treatment.

Findings:

  • Erlotinib treatment led to significant inflammation in actinic keratoses.
  • Partial regression of these pre-cancerous skin lesions was noted.
  • The observed inflammation in AKs appeared to spontaneously decrease over time while treatment continued.

Implications:

  • The inflammatory reaction in actinic keratoses may serve as a surrogate marker.
  • This accessible skin reaction could potentially predict therapeutic efficacy in deeper, targeted neoplasms.
  • Further research could explore using skin lesion responses to guide erlotinib therapy.

More Related Videos

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular cells,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...